Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CE 004

Drug Profile

CE 004

Alternative Names: CE-004

Latest Information Update: 02 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cello Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Gastric cancer; Head and neck cancer; Leukaemia; Liver cancer; Lung cancer; Lymphoma; Multiple myeloma; Ovarian cancer; Prostate cancer; Thyroid cancer

Most Recent Events

  • 19 May 2021 Cello Therapeutics in-licenses technology for nanoparticle development from Arytha Biosciences before May 2021 (Cello Therapeutics website, May 2021)
  • 19 May 2021 Cello Therapeutics has patent protection for membrane encapsulate nanoparticles in Taiwan, China, Macao, Japan, Europe (Cello Therapeutics website, May 2021)
  • 19 May 2021 Cello Therapeutics has patents pending for membrane encapsulate nanoparticles in Hong Kong, China, USA, Europe, Canada and worldwide (Cello Therapeutics website, May 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top